[Radiofrequency ablation of tumours of the lung and mediastinal lymph nodes]

Warmuth M, Nachtnebel A
Record ID 32012000770
German
Authors' objectives: Radiofrequency ablation (RFA) is a relatively new, minimally-invasive ablation method that destroys tumors by local application of heat. This systematic review evaluates the following indications of RFA for the treatment of thoracic tumors: primary lung cancer, lung metastases (associated with primary carcinomas of the breast, prostate, colon and rectum) and tumors of mediastinal lymph nodes.
Authors' recommendations: According to GRADE, the quality of evidence of the included RCT is very low due to major methodological flaws. Moreover, the quality of evidence of the included case-series is very low due their uncontrolled study design. Overall, the available evidence is insufficient to assess the efficacy and safety of RFA compared to the respective standard therapy for the treatment of lung tumors. Additionally, there is no evidence concerning RFA for the treatment of tumors of mediastinal lymph nodes. Currently, the inclusion into the hospital benefit catalogue is not recommended.
Details
Project Status: Completed
Year Published: 2012
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Austria
MeSH Terms
  • Catheter Ablation
  • Lymph Nodes
Contact
Organisation Name: Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address: Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name: tarquin.mittermayr@aihta.at
Contact Email: office@aihta.at
Copyright: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.